High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes

Prescreening of participants in clinical trials that use adeno-associated virus (AAV) vectors is required to identify naive participants, as preexisting neutralizing antibodies can limit the efficacy of AAV gene therapies. The presence of antibodies to individual AAV serotypes is typically detected...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Matthew R. Gardner, Desiree E. Mendes, Claudia P. Muniz, José M. Martinez-Navio, Sebastian P. Fuchs, Guangping Gao, Ronald C. Desrosiers
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Elsevier 2022-03-01
Цуврал:	Molecular Therapy: Methods & Clinical Development
Нөхцлүүд:	adeno-associated virus AAV capsid serotype ELISA neutralization assay
Онлайн хандалт:	http://www.sciencedirect.com/science/article/pii/S2329050122000043
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!